98%
921
2 minutes
20
Objective: To investigate changes in plasma endothelial cell-specific molecule-1 (ESM-1) concentrations following mitral regurgitation (MR) induction in dogs and to evaluate their association with established diagnostic markers of myxomatous mitral valve disease.
Methods: Purpose-bred Beagles were enrolled in a prospective, nonrandomized, controlled trial from January 2024 through March 2025. Mitral regurgitation was induced in each dog via a minimally invasive intervention under fluoroscopic guidance with mean left atrial pressure monitoring. Plasma ESM-1 concentrations were measured at baseline, 30 minutes postoperatively (PO), and 6 weeks PO. Plasma atrial natriuretic peptide concentrations and hemodynamic, radiographic, and echocardiographic variables were evaluated at baseline and 6 weeks PO.
Results: All 6 Beagles enrolled in the study developed pathological MR without clinical signs. Their plasma ESM-1 concentrations significantly increased at 6 weeks PO from the baseline, whereas no significant change was observed at 30 minutes PO. The ESM-1 concentration was positively correlated with the left atrial-to-aortic diameter ratio, peak early diastolic transmitral velocity, and early diastolic transmitral velocity-to-early diastolic mitral annular velocity. No significant correlations were found for other variables.
Conclusions: Experimentally induced MR led to a delayed but significant increase in plasma ESM-1 concentrations, which were positively associated with echocardiographic indicators of diastolic dysfunction and left atrial volume overload. Endothelial cell-specific molecule-1 expression and acute mean left atrial pressure elevation were not associated.
Clinical Relevance: Plasma ESM-1 concentrations may reflect early endothelial glycocalyx degradation during the asymptomatic stages of myxomatous mitral valve disease and represent a potential endothelial injury biomarker in veterinary cardiology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2460/ajvr.25.05.0171 | DOI Listing |
Objective: To investigate changes in plasma endothelial cell-specific molecule-1 (ESM-1) concentrations following mitral regurgitation (MR) induction in dogs and to evaluate their association with established diagnostic markers of myxomatous mitral valve disease.
Methods: Purpose-bred Beagles were enrolled in a prospective, nonrandomized, controlled trial from January 2024 through March 2025. Mitral regurgitation was induced in each dog via a minimally invasive intervention under fluoroscopic guidance with mean left atrial pressure monitoring.
Clin Kidney J
March 2024
Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
Background: The links between chronic kidney disease (CKD) and the high burden of cardiovascular disease remain unclear. We aimed to explore the association between selected inflammatory and angiogenic biomarkers, kidney function and long-term outcome in patients with an acute coronary syndrome (ACS) and to test the hypothesis that CKD status modifies this association.
Methods: A total of 1293 ACS patients hospitalized between 2008 and 2015 were followed until 31 December 2017.
Int J Mol Sci
March 2024
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", 021105 Bucharest, Romania.
Endocan is an endothelial-cell-specific proteoglycan (ESM-1) and has emerged as an endothelial dysfunction and inflammatory marker in recent years. Endocan can be used as a marker of inflammatory endothelial dysfunction in endothelium-dependent disease: cardiovascular disease, sepsis, lung and kidney disease and malignancies. Recent data suggest that endothelial dysfunction is a key mechanism in COVID-19 pathogenesis.
View Article and Find Full Text PDFPediatr Rep
September 2023
Department of Pediatrics, Medical University Pleven, 5800 Pleven, Bulgaria.
Objective: Early diagnosis of nosocomial infections in newborns is a great challenge, because in the initial phase of systemic infection, clinical symptoms are often non-specific, and routinely used hematological markers are not sufficiently informative. The aim of this study was to determine the potential of early inflammatory markers to diagnose late-onset neonatal sepsis-procalcitonin (PCT), interleukin 6 (IL-6), interleukin 8 (IL-8) and endocan (ESM-1).
Material And Methods: A prospective clinical-epidemiological study was conducted in a third-level NICU in Pleven, Bulgaria.
Oxid Med Cell Longev
November 2022
Department of Cardiology, Xuzhou Central Hospital, Xuzhou 221009, China.
The biomarkers galectin-3 (Gal-3) and endothelial cell-specific molecule 1 (ESM-1) reflect endothelial function and inflammation. As a consequence, they play an important role in both the diagnosis and characterization of ST-segment elevation myocardial infarction (STEMI). However, no prior study has explored the association between ESM-1 and Gal-3 in STEMI patients.
View Article and Find Full Text PDF